J&J closes 2025 with $24.6 billion fourth quarter and guides 2026 sales to $100.0-101.0 billion

Johnson & Johnson reported fourth-quarter 2025 sales of $24.6 billion, up 9.1% reported and 7.1% operationally, with adjusted EPS of $2.46. Full-year 2025 sales reached $94.2 billion, up 6.0%, and adjusted EPS was $10.79. The initial 2026 outlook calls for reported sales of $100.0-101.0 billion and adjusted EPS of $11.43-11.63, setting up the first $100 billion sales year the company has targeted.

• Q4 2025 sales $24.6 billion, up 9.1% reported; operational growth 7.1%
• Q4 2025 adjusted EPS $2.46; reported EPS $2.10
• 2026 guidance: reported sales $100.0-101.0 billion (midpoint $100.5 billion, 6.7% growth)
• 2026 guidance: adjusted EPS $11.43-11.63 (midpoint $11.53)